SecBot SecBot
SECBOTREPLAY Home › Report › EBS

EBS · Emergent BioSolutions announced a $54 million contract extension with…

Emergent BioSolutions · PRESS-RELEASE filed Mar 25, 2026 at 16:15 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Mar 25, 2026 at 16:15 ET

Emergent BioSolutions announced a $54 million contract extension with the U.S. government for VIGIV, a treatment for smallpox vaccine complications, and $6.6 million in new international orders for its ACAM2000 smallpox vaccine. These contracts reinforce the company's role in global biodefense preparedness and follow recent agreements with Canada worth up to $140 million CAD.

  • Secured $54 million USD U.S. government contract (ASPR) for CNJ-016® (VIGIV) under an existing 10-year agreement
  • Received $6.6 million USD in new international orders for ACAM2000® smallpox vaccine from a recurring customer
  • Recent multi-year agreements with Government of Canada valued up to $140 million CAD, with over $35 million CAD expected in 2026
  • Contracts support national and global biodefense strategies amid rising biological threat concerns

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access